ETROLIZUMAB AS INDUCTION AND MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM THE PHASE 3 BERGAMOT STUDY

William Sandborn  ¹     Julian Panés  ²     Silvio Danese  ³     Zaineb Sharafali  ⁴     Azra Hassanali     Rhian Jacob  ⁵     Chistopher Eden     Marco Daperno  ⁶     John F. Valentine  ⁷     David Laharie  ⁸     Carolina de Paula Guimarães Baía  ⁹     Raja Atreya  ¹⁰     Remo Panaccione  ¹¹     Grazyna Rydzewska-Wyszkowska  ¹²     Humberto Aguilar  ¹³     Severine Vermeire  ^14    
1 University of California San Diego, San Diego, United States
² Hospital Clínic Barcelona, Barcelona, Spain
³ Vita-Salute San Raffaele University - IRCCS San Raffaele Scientific Institute, Milan, Italy
⁴ Genentech, Inc., South San Francisco, United States
⁵ F. Hoffmann-La Roche AG, Basel, Switzerland
⁶ Gastroenterology Unit, A.O. Mauriziano “Umberto I”, Torino, Italy
⁷ University of Utah, Salt Lake City, United States
⁸ CHU de Bordeaux Hopital Haut-Leveque Dept. de Gastroenterologie, Pessac cedex, France
⁹ Médica Gastroenterologista em Belo Horizonte, Minas Gerais, Brazil
¹⁰ University Erlangen-Nuremberg, Erlangen, Germany
¹¹ University of Calgary, Calgary, Canada
¹² Centralny Szpital Kliniczny MSW w Warszawie, Warsaw, Poland
¹³ GastroIntestinal Specialists, Shreveport, United States
¹⁴ University Hospital Leuven, Leuven, Belgium

Topic
IBD, Nurses, Primary Care

Session
Clinical trials in Crohn's disease

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)